Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients

Guillaume Dumas, Anoosha Habibi, Thierry Onimus, Jean‐Claude Merle, Keyvan Razazi, Armand Mekontso Dessap, Frédéric Galactéros, Marc Michel, Véronique Frémeaux‐Bacchi, France Pirenne, Pablo BartolucciBlood 2016 · DOI · OpenAlex

Abstract

To the editor: Delayed hemolytic transfusion reaction (DHTR) with hyperhemolysis is a potentially life-threatening complication of sickle cell disease (SCD) occurring 5 to 20 days after transfusion.[1][1] Patients display symptoms of severe vaso-occlusive crisis (VOC), associated with the
BibTeX
@inproceedings{dumas2016eculizumab,
  author = {Guillaume Dumas and Anoosha Habibi and Thierry Onimus and Jean‐Claude Merle and Keyvan Razazi and Armand Mekontso Dessap and Frédéric Galactéros and Marc Michel and Véronique Frémeaux‐Bacchi and France Pirenne and Pablo Bartolucci},
  title = {{Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients}},
  booktitle = {Blood},
  year = {2016},
  doi = {10.1182/blood-2015-09-669770},
}

Loading related content...

Figure